Rockwell Signs Supply Contract With NxStage(R); VIVUS Confirms Receipt of Notice of Nomination Print E-mail
By Staff and Wire Reports   
Saturday, 09 March 2013 01:42
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 8, 2013.

Rockwell Medical (NASDAQ:RMTI)
, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced that it has signed a contract with NxStage® Medical, Inc. to manufacture dialysate concentrate for the NxStage System One", the first and only truly portable hemodialysis system cleared for home use by the U.S. FDA. The contract term is for two years.

Rob Chioini, Chairman, CEO and President of Rockwell, stated, "We are pleased to enter into a supply relationship with NxStage, a leader in home hemodialysis."


, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, confirmed that affiliates of First Manhattan Co., which disclosed beneficial ownership of approximately 8.8% of the outstanding shares of VIVUS, submitted to the Company a notice of nomination of six director candidates to stand for election to the VIVUS Board of Directors at the Company's 2013 Annual Meeting of Stockholders. VIVUS stockholders are not required to take any action at this time.

The Company will review First Manhattan's notice to ensure it complies with the Company's governing documents and applicable law. The Company's Board of Directors and Nominating and Governance Committee will consider the nominations in due course.

VIVUS issued the following statement:  The VIVUS Board of Directors and management team are committed to acting in the best interests of the Company and all VIVUS stockholders and we have had an open dialogue with First Manhattan since we first became aware of its investment in our company.

The VIVUS Board and management team are committed to building value for all stockholders. The Board is actively engaged in overseeing management's execution of the Company's stated strategy of capitalizing on the large and growing opportunities for its Qsymia® and STENDRA" franchises. VIVUS is executing the initial phases of its launch and commercialization strategy and successfully expanding the clinical awareness and acceptance of Qsymia as the Company pursues opportunities to expand patient access to this best-in-class therapeutic. VIVUS also continues to make meaningful progress in obtaining additional reimbursement coverage. VIVUS believes in the value of its franchises, and the Company's 2013 goals are to continue expanding access, through REMS modification, as well as reimbursement for Qsymia, and securing partnerships for STENDRA. The Board is confident that the achievement of these objectives will create value for all VIVUS stockholders.

VIVUS noted that its Board of Directors comprises six highly qualified and experienced directors, four of whom are independent, including the Chairman of the Board, and all of whom are elected annually. VIVUS's directors are proven business leaders with a broad range of management, financial, clinical, and operational experience, as well as expertise in the biopharmaceutical industry and other areas important to VIVUS. VIVUS has added three new directors to the Board since 2008, including one within the last twelve months.

The Company will present its recommendation with respect to the election of directors in its proxy statement to be filed with the Securities and Exchange Commission.

Also Friday:

Abattis Bioceuticals Corp. (CNSX: FLU) (OTC: ATTBF)
, is pleased to announce its participation in a research project led by Pamela Weathers, Professor of Biology and Biotechnology at Worcester Polytechnic Institute (WPI) in Worcester, Mass. that is investigating a whole plant therapeutic for treating malaria and other diseases, one that may also reduce drug resistance.

Advanced Cell Technology, Inc. (OTCBB: ACTC)
, a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present and participate on a panel at BIO-Europe Spring 2013, March 11-13, in Barcelona, Spain.

ARCA biopharma, Inc. (Nasdaq: ABIO)
, a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, announced today that Dr. Michael Bristow, President and Chief Executive Officer, will present “The Changing Paradigms in Drug Development” at conference session “Joint Symposium of the Heart Failure Society and the American College of Cardiology II: Heart Failure Care in the Era of Health Care Reform” at the American College of Cardiology 62nd Annual Scientific Sessions & Expo, being held March 9-11, 2013 in San Francisco, California.

BrainStorm Cell Therapeutics (OTCQB: BCLI)
, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2013) this week in Florence, Italy (

China Biologic Products, Inc. (NASDAQ: CBPO)
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and fiscal year 2012 financial results on Wednesday, March 13, 2013 after the market closes.

Dyax Corp. (NASDAQ: DYAX)
today announced that Ivana Magovcevic-Liebisch, Ph.D., J.D., Executive Vice President, Chief Operating Officer, will leave the Company to pursue a senior management opportunity at a multinational pharmaceutical company, effective March 29, 2013.

Endeavor Power Corporation (OTCQB: EDVP)
introduces its proprietary FDA Cleared Target System Platform Immunoassay Testing Technology ("Target System").

Esterline Corporation (NYSE: ESL)
, a leading specialty manufacturer serving aerospace/defense markets, today announced that it will redeem all of its 6.625% Senior Notes due 2017 (the "Notes") that remain outstanding on April 9, 2013.

The Medicines Company (NASDAQ: MDCO)
has scheduled a conference call and webcast following release of the Phase 3 cangrelor CHAMPION PHOENIX trial results on Sunday, March 10, 2013 at 11:00 a.m. Pacific Time, 2:00 p.m. Eastern Time.

Pharmacyclics, Inc. (NASDAQ: PCYC)
, a clinical stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, today announced the pricing of a previously announced underwritten registered public offering of 2,200,000 shares of its common stock, representing approximately 3.1% of the shares of common stock currently outstanding, at a public offering price of $94.20 per share.

Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT)
--Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment.

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX)
(“the Company” or “RegeneRx”) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office claiming compositions and methods for treating, preventing, inhibiting, reducing, or repairing tissue deterioration, injury or damage due to heart failure using Thymosin beta 4 (Tβ4), its isoforms and fragments, derivatives and analogs.

Retrophin, Inc. (OTCQB: RTRX)
, a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced that Martin Shkreli, founder and chief executive officer, will be presenting at the 25th Annual ROTH Conference, which is being held March 17-20 in Dana Point, CA.

St. Jude Medical, Inc. (NYSE:STJ)
, a global medical device company, today announced the first patient implant in a new pivotal trial evaluating the company’s AMPLATZER™ Cardiac Plug (ACP) for the prevention of stroke.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus